Metabolic Diseases

MASLD/MASH : Metabolic-associated liver diseases

Nonalcoholic fatty liver disease (MASLD) is a condition in which excess fat is stored in the liver, independently of alcohol use. Nonalcoholic hepatic steatosis (MASH) is a form of MASLD in which, in addition to an increase in fat content, the liver shows a sustained level of inflammation, called hepatitis, and cell damage. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver. MASH may lead to cirrhosis or liver cancer. The worldwide prevalence of MASLD and MASH has been estimated at 25% and around 1.5-6.5% respectively. However, to date, and despite the high medical need, Resmetirom is the only approved therapy for MASH.

of people affected 
worldwide

> 0 BN

Global Health costs
for MASLD/MASH

> 0 bn

pharmaceutical  
treatment to date

0 1

Models

We have a long track record in conduction preclinical studies on MASLD and MASH on a variety of established and validated rodent models for chronic efficacy and MoA studies.

Nutritional models

DIO MASLD mouse model
DIO MASH mouse model
STZ-DIO mouse model

Methods

We master gold-standard methods to provide you with high-added value data about your health products efficacy and mechanisms of action on key hallmarks of MASLD/MASH such as food intake, body weight, circulating plasma biomarkers (ALT/AST…). In addition, we offer complementary techniques that allow performing histological and genomic analyses on key tissues and organs.